Evommune (EVMN) Payables (2024 - 2026)

Evommune (EVMN) has 3 years of Payables data on file, last reported at $4.0 million in Q1 2026.

• On a quarterly basis, Payables changed N/A year-over-year to $4.0 million in Q1 2026; TTM through Mar 2026 was $4.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $7.8 million, down 6.15% from the prior year.
• Payables for Q1 2026 stood at $4.0 million, down from $7.8 million in the prior quarter.
• Over the last five years, Payables for EVMN reached as high as $8.3 million in Q4 2024 and fell as low as $3.6 million in Q3 2025.
• Historically, Payables has averaged $5.9 million across 3 years, with a median of $5.9 million in 2025.
• On a YoY basis, Payables climbed as much as 6.15% in 2025 and fell as far as 6.15% in 2025.
• Year by year, Payables stood at $8.3 million in 2024, then dropped by 6.15% to $7.8 million in 2025, then tumbled by 47.85% to $4.0 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $4.0 million in Q1 2026, $7.8 million in Q4 2025, and $3.6 million in Q3 2025.